PCI-32765

DRUG13 trials

Sponsors

Pharmacyclics LLC., M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Janssen Pharmaceutical K.K., Janssen Research & Development, LLC

Conditions

B Cell LymphomaB-Cell Diffuse LymphomaB-Cell LeukemiaB-Cell LymphomaB-cell Chronic Lymphocytic LeukemiaBurkitt LymphomaDiffuse Well-differentiated Lymphocytic LymphomaFollicular Lymphoma

Phase 1

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

CompletedNCT00849654

Pharmacyclics LLC.B-Cell Leukemia, B-Cell Lymphoma

Start: 2009-02-28End: 2012-07-31Updated: 2013-05-22

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

CompletedNCT01105247

Pharmacyclics LLC.B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2010-05-31End: 2013-02-28Updated: 2014-03-31

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

CompletedNCT01217749

Pharmacyclics LLC.B-cell Chronic Lymphocytic Leukemia, Prolymphocyctic Leukemia, Richter's Transformation +1

Start: 2010-12-31End: 2014-05-31Updated: 2015-06-25

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01292135

Pharmacyclics LLC.B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2011-02-28End: 2013-05-31Updated: 2014-07-24

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

CompletedNCT01704963

Janssen Pharmaceutical K.K.Recurrent Mature B-cell Neoplasms

Start: 2012-09-12End: 2017-02-01Updated: 2018-02-05

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

CompletedNCT01752426

M.D. Anderson Cancer CenterLeukemia

Start: 2012-12-17End: 2018-08-09Updated: 2020-02-24

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

CompletedNCT01763021

Janssen Research & Development, LLCHealthy Participants

Start: 2012-12-31End: 2013-01-31Updated: 2013-04-17

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

CompletedNCT01767948

Janssen Research & Development, LLCHepatic Impairment

Start: 2012-12-31End: 2013-11-30Updated: 2014-10-07

Phase 2

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

CompletedNCT01109069

Pharmacyclics LLC.B-cell Chronic Lymphocytic Leukemia, B-Cell Diffuse Lymphoma, B Cell Lymphoma +7

Start: 2010-06-30End: 2019-04-26Updated: 2020-05-27

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

CompletedNCT01236391

Pharmacyclics LLC.Mantle Cell Lymphoma

Start: 2011-02-28End: 2014-01-31Updated: 2015-08-28

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

CompletedNCT01478581

Pharmacyclics LLC.Multiple Myeloma

Start: 2012-03-31End: 2018-08-31Updated: 2020-03-10

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

CompletedNCT01520519

M.D. Anderson Cancer CenterLeukemia

Start: 2012-02-27End: 2018-08-09Updated: 2019-09-18

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

CompletedNCT01614821

Dana-Farber Cancer InstituteWaldenstrom's Macroglobulinemia

Start: 2012-05-31End: 2018-09-15Updated: 2020-01-21

Related Papers

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Blood2025-11-031 citations

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Blood2025-11-03

Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis

Blood Advances2025-07-17

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

2024-11-124 citations

Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study

Blood2024-11-05

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with <i>IGHV</i>, ZAP-70, and MRD

Blood2024-10-233 citations

Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.

Journal of Clinical Oncology2023-06-019 citations

High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood2022-11-15

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

Clinical Hematology International2022-09-1414 citations

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research2020-03-24175 citations

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Blood2019-11-1324 citations

Recent Developments in the Treatment of Mantle Cell Lymphoma

Oncology Times2019-07-31

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Blood Advances2019-06-13127 citations

PF494 CLINICAL OUTCOMES WITH SINGLE‐AGENT IBRUTINIB FOR RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): INTERIM ANALYSIS (IA) OF THE BELGIAN IBRUTINIB REAL‐WORLD DATA (BIRD) STUDY

HemaSphere2019-06-011 citations

PS1264 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR MANTLE CELL LYMPHOMA (MCL) IN FRANCE

HemaSphere2019-06-01

PS1265 IMPROVEMENTS IN OUTCOME OF MANTLE-CELL LYMPHOMA (MCL) ARE MOSTLY DUE TO ADVANCES IN INDUCTION THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) – A REAL-LIFE NON-INTERVENTIONAL STUDY OF KROHEM

HemaSphere2019-06-01

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood2018-11-2916 citations

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Blood2018-11-297 citations

Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database

Blood2018-11-292 citations

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

JAMA Oncology2018-02-2221 citations

22 more papers not shown